
    
      The safety, tolerability and antiviral activity of ANA598, administered orally twice daily
      for 3 days, will be compared to placebo in treatment-na√Øve subjects chronically infected with
      HCV genotype 1 infection. Thirty (30) subjects will be randomized to one of three cohorts
      described above. The ten patients in each cohort will be randomized 8 active: 2 placebo. At
      least 5 subjects with genotype 1a and 5 subjects with genotype 1b will be enrolled within
      each cohort.
    
  